A. Akshaya,
- UG Student II BCA, Saveetha Institute of Medical and Technical Sciences, Tamil Nadu, India
Abstract
The drug industry is a complex field that involves legal medicines and illegal substances. It affects many aspects of society, including health, the economy, crime, and how people interact. This industry includes both medicines prescribed by doctors and drugs that are not allowed, each with its own effects. Lately, drug abuse has become a big problem, affecting people of all ages. Using drugs, whether legal or not, can harm health and lead to addiction, physical problems, and mental health issues. Selling illegal drugs also causes more problems, like crime and safety concerns. To address these challenges, we need a combination of approaches. Educational campaigns help people understand the dangers of using drugs, especially young people. Laws and police work focus on stopping the making, selling, and movement of illegal drugs, aiming to break up criminal groups. The future of the drug industry is connected to technology, how the world is getting more connected, and how people’s ideas are changing. New medicines can help, but they also bring challenges in terms of safety and use. It’s important to find a balance between helping people with medicines and stopping them from being misused.
Keywords: Drug industry, Economy, Educational campaigns, Medicines, Technology.
[This article belongs to Research & Reviews: A Journal of Pharmaceutical Science ]
A. Akshaya. Substance Misuse Fallout: Investigating the Multifaceted Consequences Experienced by Individuals in the Realm of Drug Abuse. Research & Reviews: A Journal of Pharmaceutical Science. 2024; 15(01):45-52.
A. Akshaya. Substance Misuse Fallout: Investigating the Multifaceted Consequences Experienced by Individuals in the Realm of Drug Abuse. Research & Reviews: A Journal of Pharmaceutical Science. 2024; 15(01):45-52. Available from: https://journals.stmjournals.com/rrjops/article=2024/view=143336
References
1. Volkow, N. D., & Koob, G. F. (2015). Brain disease model of addiction: Why is it so controversial? The Lancet Psychiatry, 2(8), 677-679.
2. Degenhardt, L., Charlson, F., Stanaway, J., Larney, S., Alexander, L. T., Hickman, M., … & Hall, W. D. (2016). Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. The Lancet Infectious Diseases, 16(12), 1385-1398.
3. Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009). Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. The Lancet, 373(9682), 2223-2233.
4. French, M. T., Popovici, I., & Tapsell, L. (2008). The economic costs of substance abuse treatment: Updated estimates and cost bands for program assessment and reimbursement. Journal of Substance Abuse Treatment, 35(4), 462-469.
5. Gerra, G., Zaimovic, A., Giusti, F., Moi, G., Brewer, C., & Green, J. L. (2000). Dexamethasone suppression test in chronic heroin users: relationship to depression and other variables. Comprehensive Psychiatry, 41(2), 130-135.
6. Grant, B. F., Saha, T. D., Ruan, W. J., Goldstein, R. B., Chou, S. P., Jung, J., … & Hasin, D. S. (2016). Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions–III. JAMA Psychiatry, 73(1), 39-47.
7. Copello, A. G., & Orford, J. (2002). Addiction and the family: is it time for services to take notice of the evidence? Addiction, 97(11), 1361-1363.
8. Laudet, A. B., Savage, R., & Mahmood, D. (2002). Pathways to long-term recovery: A preliminary investigation. Journal of Psychoactive Drugs, 34(3), 305-311.
9. Wilcox, H. C., Conner, K. R., & Caine, E. D. (2004). Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies. Drug and Alcohol Dependence, 76(Supplement 1), S11-S19.
10. Karriker-Jaffe, K. J. (2011). Areas of disadvantage: A systematic review of effects of area-level socioeconomic status on substance use outcomes. Drug and Alcohol Review, 30(1), 84-95.
11. McLellan, A. T., Lewis, D. C., O’Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA, 284(13), 1689-1695.
12. Kelly, J. F., Bergman, B., Hoeppner, B., Vilsaint, C., & White, W. L. (2017). Prevalence, pathways, and predictors of recovery from drug and alcohol problems in the United States population: Implications for practice, research, and policy. Drug and Alcohol Dependence, 181, 162-169.
Research and Reviews: A Journal of Pharmaceutical Science
| Volume | 15 |
| Issue | 01 |
| Received | 16/02/2024 |
| Accepted | 01/04/2024 |
| Published | 15/04/2024 |